Actemra CAR-T-Related Indication Comes With Help From Novartis, Kite, US FDA

31 Aug 2017

Genentech's interleukin-6 inhibitor got bonus approval based on data from development programs for Novartis' and Kite's chimeric antigen receptor T-cell therapies; CAR-T developers allowed FDA to access the Actemra-related data in their applications and conduct its own pooled analysis.

T-cells attacking cancer_1200x675 — FDA approved Genentech's Actemra for treating CAR-T cell-related cytokine release syndrome

Actemra CAR-T-Related Indication Comes With Help From Novartis, Kite, US FDA

More from Approvals

More from Product Reviews